Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLUTAMICS III: Glutamate infusion for prevention of acute kidney injury in ischemic heart disease surgery
2024-513575-40-01Phase 3Authorised
- Sponsor
- Region Östergötland
- Start
- Sep 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Glutamic acid in acute kidney failure (AKF), heart failure (HF) and coronary arteriosclerosis (2 arms), sponsored by Region Östergötland. Primary endpoint: Incidence of postoperative acute kidney injury. Planned start Sep 2024; status: authorised.
02
Drugs
Glutamic acid
03
Conditions
acute kidney failure (AKF)heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on 2024-513575-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513575-40-01.